Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue BMC Cancer Année : 2005

Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.

Résumé

BACKGROUND: Median survival of metastatic malignant melanoma is 6.0 to 7.5 months, with a 5-year survival of approximately 6.0%. Although long-term complete remissions are rare, few reports describe cases after chemotherapy. Fifty-three patients with metastatic melanoma were treated with Cystemustine, a chloroethyl nitrosourea (CENU) (60 or 90 mg/m2). CASE PRESENTATION: We describe 5 cases, presenting with complete response with long-term disease-free survival of long-term remission of 14, 12, 9, 7 and 6 years after Cystemustine therapy alone. CONCLUSION: Long-term survival has already been described in literature, but in all cases they have been obtained after chemotherapy associated with or followed by surgery. But despite these noteworthy and encouraging but also rare results, it appears essential to increase Cystemustine efficiency.

Domaines

Cancer
Fichier principal
Vignette du fichier
1471-2407-5-147.pdf (144.38 Ko) Télécharger le fichier
Loading...

Dates et versions

inserm-00089310 , version 1 (17-08-2006)

Identifiants

Citer

Xavier Durando, Emilie Thivat, Michel d'Incan, Anne Sinsard, Jean-Claude Madelmont, et al.. Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.. BMC Cancer, 2005, 5, pp.147. ⟨10.1186/1471-2407-5-147⟩. ⟨inserm-00089310⟩
154 Consultations
393 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More